Innoviva to Participate in the UBS Global Healthcare Conference

INVA 11.12.2024

Full Press ReleaseSEC FilingsOur INVA Tweets

About Gravity Analytica

Recent News

  • 12.16.2024 - Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
  • 12.05.2024 - Citi 2024 Global Healthcare Conference
  • 11.26.2024 - Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Recent Filings

  • 11.22.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - SC 13D/A General Statement of Acquisition of Beneficial Ownership
  • 11.06.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
PDF Version

BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 12, 2024--Innoviva, Inc.(NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at theUBS Global Healthcare Conferencein Ranch Palos Verdes, CA onWednesday, November 13, 2024at10:15 a.m. Pacific Time.

A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website athttps://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.

AboutInnoviva

Innovivais a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered withGlaxo Group Limited(“GSK”).Innovivais entitled to receive royalties from GSK on sales of RELVAR®/BREO®ELLIPTA®and ANORO®ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions ofEntasis Therapeutics, including XACDURO®(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, andLa Jolla Pharmaceutical Company, including GIAPREZA®(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA®(eravacycline) for the treatment of complicated intra-abdominal infections in adults.

ANORO®, RELVAR®and BREO®are trademarks of the GSK group of companies.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241112829799/en/

Innoviva, Inc.David PattiCorporate Communications(908) 421-5971david.patti@inva.com

Investors and Media:Argot Partners(212) 600-1902innoviva@argotpartners.com

Source:Innoviva, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com